Last updated: February 27, 2026
What is the Product's Market Position?
NDC 29300-0255 corresponds to Pirtobrutinib (formerly known as LOXO-305). This drug is a next-generation, highly selective Bruton’s tyrosine kinase (BTK) inhibitor developed for relapsed or refractory B-cell malignancies, including chronic lymphocytic leukemia (CLL), mantle cell lymphoma, and Waldenström's macroglobulinemia.
This product has completed Phase 1/2 trials and has shown promising efficacy in patients who have failed other BTK inhibitors. It is positioned as a potential competitor to existing BTK inhibitors such as Ibrutinib and Acalabrutinib.
Regulatory Status
As of Q1 2023, Pirtobrutinib is under review by the U.S. Food and Drug Administration (FDA) with a priority review designation, targeting potential approval within the next 12 months. Its European regulatory pathway is under evaluation by the European Medicines Agency (EMA).
Market Size Overview
Target indications:
- Chronic lymphocytic leukemia (CLL)
- Mantle cell lymphoma (MCL)
- Waldenström's macroglobulinemia
Global prevalence estimates (2023):
| Disease |
Prevalence |
Market Detail |
| CLL |
150,000 in the U.S. |
Largest segment; established standard of care involves BTK inhibitors. |
| MCL |
3,000–5,000 in the U.S. |
Smaller but significant for targeted therapies. |
| Waldenström's |
~3,000 in the U.S. |
Niche but growing segment. |
The US market for relapsed/refractory B-cell malignancies exceeds $4 billion annually, with BTK inhibitor treatments comprising a major share.
Competitive Landscape
Key Competitors:
| Drug Name |
Approval Status |
Key Features |
Estimated Annual Sales (2022) |
| Ibrutinib (Imbruvica) |
FDA approved (2013) |
First-in-class BTK inhibitor |
~$6.5 billion |
| Acalabrutinib (Calquence) |
FDA approved (2019) |
More selective, fewer off-target effects |
~$2.5 billion |
| Zanubrutinib (Bruksvia) |
Approved in several markets |
Similar efficacy, different safety profile |
~$1 billion |
Pirtobrutinib aims to offer improved efficacy in patients resistant to existing BTK inhibitors and fewer adverse effects, potentially capturing market share in refractory cases.
Price and Revenue Projections
Current Pricing
- Ibrutinib: Approximate wholesale price per average dose is $10,000–$12,000.
- Acalabrutinib: $9,500–$11,000.
- Zanubrutinib: $8,500–$10,000.
Projected Pricing for Pirtobrutinib
Based on market positioning, clinical trial data, and comparator analysis:
- Estimated wholesale price: $8,500–$10,000 per month.
- Compared to competitors, Pirtobrutinib may price at a slight discount to attract payers and clinicians for resistant cases.
Revenue Projections (2024–2028)
| Year |
Estimated Annual Sales |
Assumptions |
Notes |
| 2024 |
$200 million |
Initial adoption in refractory patients; 5% of relapsed cases |
During launch phase; limited by regulatory approval timeline. |
| 2025 |
$850 million |
Broader adoption in second-line treatments |
Increased acceptance, expanded indications. |
| 2026 |
$1.5 billion |
Market penetration increases; potential expansion into earlier lines |
Competitors may introduce generics or biosimilars. |
| 2027 |
$2 billion |
Growing confidence; potential for combination therapies |
Payer negotiations influence pricing strategies. |
| 2028 |
$2.5 billion |
Market saturation; entrance to international markets |
Global rollout and expanded labeling. |
Analysts project a compound annual growth rate (CAGR) of approximately 50% in early years, tapering to 20–25% upon market maturity.
Key Factors Influencing Price and Market Dynamics
- Regulatory outcome: Approval status directly impacts market entry timing.
- Reimbursement landscape: Payer coverage policies influence achievable net prices.
- Clinical positioning: Superior safety/efficacy in resistant patients enhances adoption.
- Patent lifespan: Patent expiry predicted around 2033, affecting long-term pricing.
- Market competition: Biosimilars or next-generation drugs may drive prices downward.
Conclusion
Pirtobrutinib’s market entry is poised for rapid growth if regulatory approval occurs as projected. Pricing is likely to be set competitive with existing BTK inhibitors, with initial wholesale prices in the $8,500–$10,000 monthly range. Revenue potential reaches up to $2.5 billion annually by 2028, with significant growth expected through expanded indications and international markets.
Key Takeaways
- NDC 29300-0255 (Pirtobrutinib) is in late-stage development targeting refractory B-cell malignancies.
- The primary competitors are Ibrutinib and Acalabrutinib, with prices in the $9,000–$12,000 range monthly.
- Projected wholesale price for Pirtobrutinib is $8,500–$10,000 per month, depending on payer negotiations.
- Sales could reach $2.5 billion annually by 2028, assuming successful regulatory approval and broad clinical adoption.
- Market growth depends on clinical outcomes, competitive dynamics, and regulatory decisions.
FAQs
-
When is Pirtobrutinib expected to gain FDA approval?
The FDA granted a priority review, with a decision anticipated within 12 months, likely in 2023 or early 2024.
-
What are the main advantages of Pirtobrutinib over existing BTK inhibitors?
It offers higher selectivity and efficacy in patients resistant to earlier BTK inhibitors, with potentially fewer off-target effects.
-
How does Pirtobrutinib’s pricing compare to competitors?
Its estimated wholesale price is aligned slightly below Ibrutinib and Acalabrutinib, aiming for aggressive market penetration.
-
What factors could affect Pirtobrutinib’s market success?
Regulatory outcomes, payer coverage, clinical trial results, and competition from biosimilars or other therapies.
-
What is the potential global market size for Pirtobrutinib?
The global B-cell malignancies market exceeds $6 billion annually, with expansion potential in Europe, Asia, and emerging markets.
References
[1] IQVIA. (2022). Pharmaceutical Sales Data.
[2] American Cancer Society. (2022). B-Cell Malignancies Statistics.
[3] U.S. Food and Drug Administration. (2023). Drug Review and Approval Timeline.
[4] Evaluate Pharma. (2023). Market Forecast for BTK Inhibitors.
